Industry News
51Talk Online Education Group Announces Third Quarter 2025 Results
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the third quarter endedSeptember 30, 2025. Third Quarter 2025 F...
2025-12-08 19:30
5272
Geleximco Group and China intelligent chassis solution provider Leekr Technology signed a MoU to deepen industrial collaboration
SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- Geleximco Group and Leekr Technology, a leading Chinese provider of intelligent chassis system solutions, formally signed a Memorandum of Understanding (MoU) inShanghai. By combining their respective strengths, the two companies will deepen industrial cooper...
2025-12-08 18:03
1883
Sennics Unveils Major Breakthroughs in New Eco-Friendly Antioxidant SA6000
SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- On December 8, 2025, to commemorate the second anniversary of the Seminar on Future Development Trends in Rubber Additives, Sennics showcased its research achievements from the past two years, highlighting significant progress in developing its novel eco-fri...
2025-12-08 17:01
1723
SJTU International Gen Z Students Explore Shanghai's Innovation Ecosystem
SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- Shanghai Jiao Tong University's Antai Global Summer Program (AGSP) welcomed a diverse cohort of over 80 Gen Z students from 28 leading universities across 22 countries for an immersive exploration ofShanghai's world-class innovation ecosystem (July 9-24). Th...
2025-12-08 16:57
1811
Yantai offers global bay areas a paradigm of low-carbon transformation
YANTAI, China, Dec. 8, 2025 /PRNewswire/ -- On December 4, the 2025 Shandong Green Low-carbon High-quality Development Conference was held in Yantai,Shandong province. Against the backdrop of the fifth anniversary ofChina's 'dual carbon' goals, Yantai's achievements—as one of the country's first ...
2025-12-08 16:52
2128
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first sh...
2025-12-08 14:36
2748
CIMC Unveils New Global Brand Logo and Visual Identity System
SHENZHEN, China, Dec. 7, 2025 /PRNewswire/ -- On December 5, 2025, China International Marine Containers (Group) Co., Ltd. (CIMC) unveiled its new brand logo and visual identity system to a global audience. Marking the company's most significant brand upgrade in nearly fifteen years, the launch s...
2025-12-08 10:21
4332
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...
2025-12-08 10:08
4744
Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
NANJING, China, Dec. 7, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation o...
2025-12-08 10:00
4127
IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 7, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceuticalcompany focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignanc...
2025-12-08 09:57
1851
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2025-12-08 09:02
2216
Global Times: Mogao Caves' mural paintings meet modern technology
BEIJING, Dec. 7, 2025 /PRNewswire/ -- The flying Apsaras dance across the heavens; caravan bells echo along ancient routes. Dunhuang, a pivotal hub on the ancient Silk Road, served as a crossroads where diverse civilizations converged, giving birth to the radiant splendor of the Mogao Caves. As a...
2025-12-08 08:48
1758
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...
2025-12-08 08:15
3964
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtage...
2025-12-07 17:21
4415
All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released byChina's National Healthcare Securi...
2025-12-07 14:18
2617
Skymizerʼs HyperThought™ Wins "Best IP/Processor of the Yearˮ and "Most Promising Productˮ at EE Awards Asia 2025
TAIPEI, Dec. 6, 2025 /PRNewswire/ -- Skymizer today announced that its next-generation HyperThought™ LLM Accelerator IP has been awarded "Best IP/Processor of the Yearˮ and named the "Most Promising Productˮ at the prestigious EE Awards Asia 2025, hosted by ASPENCORE at the Grand Mayfull Taipei ...
2025-12-07 12:53
2666
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-12-07 11:40
3182
SK hynix Honored with Two Major Titles at GSA Awards 2025
* Company named "Best Financially Managed Semiconductor Company (Achieving Greater than$1 Billion in Annual Sales)" and "Outstanding Asia-Pacific Semiconductor Company" simultaneously * Accelerates recovery from market downturn leveraging world-class HBM leadership; Global management performa...
2025-12-07 07:48
3188
LiberNovo Goes Global: New Markets & A Vision for Healthy Workspaces
HONG KONG, Dec. 6, 2025 /PRNewswire/ -- For the millions of programmers,
creative professionals, and remote workers battling the inertia of sedentary
work, a breakthrough moment has arrived.LiberNovo
2025-12-07 00:00
6542
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in viv...
2025-12-06 22:45
3339
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 295 media titles]
2026-08-04 07:00
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
16047
